Insilico Medicine has nominated ISM6166 as a preclinical candidate, a potent, oral pan-KRAS inhibitor designed to treat a broad spectrum of solid tumours. Among the Ras family of oncogenes, KRAS is one of the most frequently altered drivers in human cancer, playing a key role in regulating… Read More
Drug Discovery World speaks to companies at the cutting edge of innovation in blood cancer therapeutics. The prognosis for patients with blood cancers has improved dramatically since the turn of the century. Thanks to an ever-growing array of treatments becoming available, there has been significant progress in treating B cell leukaemias like acute lymphoblastic leukaemia (B-ALL), as well… Read More
The European Association of Nuclear Medicine (EANM) has launched an award for research in prostate cancer treatment. The 2026 EANM Young Scientist Network Award, aiming to accelerate innovation in alpha radioligand therapy in prostate cancer, offers three prizes of €40,000 (Platinum), €20,000 (Gold) and €10,000 (Silver). … Read More
The European Innovation Council (EIC) has awarded €2.5 million to biotechnology company Step Pharma to accelerate the development of dencatistat for CTPS2 null gynaecological tumours. The funding, which consists of a €2.5 million grant and potentially up to €10 million in equity investment, is part of the EIC’s Accelerator Award, designed to support… Read More
Starton Therapeutics announced it has dosed the first patient in its Phase IIa study evaluating STAR-LLD for the treatment of relapsed/refractory multiple myeloma (RRMM). STAR-LLD is a continuous delivery lenalidomide (LLD) in development seeking to expand and replace the standard-of-care for the most common blood cancers, multiple… Read More
A multiple myeloma (MM) drug candidate with a new mode of action from Imperial College London is now in Phase II patient trials following positive Phase I results. The first-in-class investigational drug DTP3 is designed to treat MM and other cancers, including diffuse large B-cell lymphoma (DLBCL),… Read More
A new treatment for ovarian cancer could prevent peritoneal recurrence, data suggests. Biotech company Oncoinvent is set to present results from the Phase I study of Radspherin after cytoreductive surgery in patients with platinums ensitivesensitive epithelial ovarian cancer. According to data released in advance, nine of 10 patients treated on the highest dose remained free… Read More
Cancer Research Horizons has made one the largest oesophageal cancer datasets available for commercial licensing. Developed by a team led by Professor Rebecca Fitzgerald at the University of Cambridge, the Oesophageal Cancer Clinical and Molecular Stratification (OCCAMS) dataset represents one of the world’s largest and most comprehensive collections… Read More
Lyell Immunopharma has begun its PiNACLE – H2H Phase III trial evaluating rondecabtagene autoleucel (ronde-cel, also known as LYL314) compared to lisocabtagene maraleucel (liso-cel) or axicabtageneciloleucel (axi-cel). The CAR-T therapies will be assessed in relapsed or refractory (R/R) large B-cell lymphoma (LBCL) receiving treatment in the second-line… Read More
Neomorph has commenced a Phase I/II clinical trial evaluating NEO-811, a novel investigational molecular glue degrader, in patients with locally advanced or metastatic non-resectable clear cell renal cell carcinoma (ccRCC). NEO-811 is an investigational molecular glue degrader designed to induce targeted degradation of a key disease-driving protein… Read More
Cancer Research UK has allocated £2.5 million ($3.4 million) to researchers at the University of York to help transform care for patients diagnosed with blood cancers. The funding is for the world leading Haematological Malignancy Research Network (HMRN), one of the most comprehensive blood cancer research networks in the… Read More
The London Cancer Hub has secured approval for a £1 billion ($1.4 billion) expansion, bringing state-of-the-art cancer research and lab space to the UK. London Cancer Hub’s expanded district promises to be one of the world’s most ambitious life sciences clusters, with 12 acres dedicated to accelerating cancer research, treatment and commercial… Read More
Researchers at the Texas A&M University Health Science Center have identified a novel RNA molecule that plays a crucial role in preserving the integrity of a key cellular structure, nucleolus. This research reveals an RNA molecule that regulates key cellular functions without turning into protein, thus functioning… Read More
SPT Labtech and BellBrook Labs are collaborating to advance cancer research, having developed a miniaturised, high-throughput screening platform for the discovery and profiling of Vacuolar protein sorting associated protein 4B (VPS4B) ATPase inhibitors. VPS4B has emerged as a high-priority therapeutic target in oncology due to its overexpression in specific tumours and its… Read More
Slingshot Therapeutics has launched ALTx Therapeutics with funding worth £12.55 million ($17.04 million) to develop novel treatments for cancer. ALTx Therapeutics launched into the Slingshot accelerator with backing from Syncona, the Francis Crick Institute and Cancer Research Horizons. Spinning out of the Crick, ALTx is focused on developing therapeutics targeting vulnerabilities in cancers that rely on… Read More
The European Medicines Agency (EMA)’s Committee for Medicinal Products for Human Use (CHMP) has recommended Zynyz (retifanlimab) for the treatment of anal cancer. Zynyz, developed by biopharmaceutical company Incyte, has received the EMA’s positive opinion to treat recurrent squamous cell carcinoma of the anal cancer (SCAC) in combination with… Read More
